By Adriano Marchese
Protara Therapeutics' stock jumped in premarket trading Thursday after reporting positive early results from its bladder cancer treatment trials.
Shares traded 69% higher ahead of the morning bell at $5.92.
The clinical-stage company said that patients in the intravesical trial studying its investigational cell-based therapy TARA-002 to treat non-muscle invasive bladder cancer have shown high complete response rates for up to six months, and as high as nine months for some patients.
The dataset includes 20 patients who were evaluable at three months, 18 patients who were evaluable at six months and three patients who were evaluable at nine months.
The trials are still ongoing, but Chief Executive Jesse Shefferman said that these are encouraging results which should be positive as it expands the breadth of the trials.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 05, 2024 08:44 ET (13:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。